miR-33 inhibitor

miR-33 inhibitors are a class of oligonucleotide-based therapeutics, including antisense oligonucleotides (ASOs) and antagomirs, designed to silence microRNA-33 (specifically miR-33a and miR-33b). miR-33 is an evolutionary conserved microRNA located within the introns of the SREBF genes that plays a critical role in regulating lipid homeostasis. Its primary mechanism involves the post-transcriptional repression of the ATP-binding cassette transporter A1 (ABCA1), which is essential for cholesterol efflux and high-density lipoprotein (HDL) biogenesis. By inhibiting miR-33, these agents de-repress ABCA1, thereby promoting reverse cholesterol transport and potentially reducing atherosclerotic plaque burden. Beyond lipid metabolism, miR-33 inhibitors are being investigated for their ability to modulate fatty acid oxidation, promote M2 macrophage polarization in inflammatory contexts, and reduce fibrosis in myocardial and muscular tissues. Research has explored various chemical modifications, such as artificial nucleic acids (AmNA), to improve the pharmacokinetic properties and stability of these inhibitors.

Other names

anti-miR-33 oligonucleotideanti-miR33 oligonucleotideanti-miR 33 oligonucleotidemiR-33 antagomirmiR33 antagomirmiR 33 antagomiranti-microRNA-33anti-microRNA33anti-microRNA 33